Tumor responses and PFS in our study were in line with other real-life clinical data and they seem to be inferior to the reported in the SELECT trial, probably related to the higher number of patients with prior MKI therapy, comorbidities, and poor performance status.
Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina
